Olsen S. Extracapillary glomerulonephritis. A semiquantitative light microscopic study of 59 patients. Acta Pathol Microbiol Scand Suppl. 1974;Suppl 249:7–19.

CAS  PubMed  Google Scholar 

Konda R, Rajasekaran A, Rizk DV. Antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Nephrol Hypertens. 2024;33:503–11.

Article  CAS  PubMed  Google Scholar 

Miskovic R, Radovic S, Arandjelovic S, et al. Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review. Rheumatol Int. 2024;44:2621–35.

Article  PubMed  Google Scholar 

Matsuzaki K, Aoki R, Nihei Y, et al. Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. Clin Exp Nephrol. 2022;26:316–22.

Article  CAS  PubMed  Google Scholar 

Łysak K, Walulik A, Błaszkiewicz M, Gomułka K. ANCA-positive small-vessel vasculitis following SARS-CoV-2 vaccination—a systematic review. Vaccines (Basel). 2024;12:656.

Article  PubMed  Google Scholar 

Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798–796.

Article  PubMed  Google Scholar 

Pillebout E. IgA vasculitis and IgA nephropathy: Same disease? J Clin Med. 2021;10:2310.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jennette JC, Thomas DB. Pauci-immune and antineutrophil cytoplasmic autoantibody-mediated crescentic glomerulonephritis and vasculitis. In: Jennette JC, Olsen JL, Silva FG, D’Agati VD, editors. Heptinstall’s pathology of the kidney. 7th ed. Wolters Kluwer; 2015. p. 685–713.

Google Scholar 

Nomura Y, Ohya N, Shimada M. A histopathological study on the prognosis of childhood IgA nephropathy and glomerular basement membrane lesions. Pediatr Nephrol. 1989;3:242–7.

Article  CAS  PubMed  Google Scholar 

Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599–609.

Article  CAS  PubMed  Google Scholar 

Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325:2178–87.

Article  CAS  PubMed  Google Scholar 

Suzuki H, Moldoveanu Z, Julian BA, Wyatt RJ, Novak J. Autoantibodies specific for galactose-deficient IgA1 in IgA vasculitis with nephritis. Kidney Int Rep. 2019;4:1717–24.

Article  PubMed  PubMed Central  Google Scholar 

Chiu YL, Lin WC, Shu KH, et al. Alternative complement pathway is activated and associated with galactose-deficient IgA1 antibody in IgA nephropathy patients. Front Immunol. 2021;12: 638309.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang YH, Tsai IJ, Chang CJ, Chuang YH, Hsu HY, Chiang BL. The interaction between circulating complement proteins and cutaneous microvascular endothelial cells in the development of childhood Henoch-Schönlein Purpura. PLoS ONE. 2015;10: e0120411.

Article  PubMed  PubMed Central  Google Scholar 

Wang Z, Xie X, Li J, et al. Complement activation is associated with crescents in IgA nephropathy. Front Immunol. 2021;12: 676919.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lundberg S, Westergren E, Smolander J, Bruchfeld A. B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis. Clin Kidney J. 2017;10:20–6.

PubMed  Google Scholar 

Lafayette RA, Canetta PA, Rovin BH, et al. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306–13.

Article  CAS  PubMed  Google Scholar 

Xiong Y, Cuevas S, Xu G, Zou H. The efficacy of rituximab in the treatment of IgA vasculitis nephritis. Clin Exp Med. 2024;24:213.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bruchfeld A, Magin H, Nachman P, et al. C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study. Clin Kidney J. 2022;15:922–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bantis C, Stangou M, Schlaugat C, et al. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis. 2010;55:259–68.

Article  CAS  PubMed  Google Scholar 

Nissaisorakarn P, D’Agati V, Anis K, Jim B. ANCA and IgA glomerulonephritis all in one: prognosis and complications. BMJ Case Rep. 2017;2017:bcr2017222080.

Article  PubMed  PubMed Central  Google Scholar 

Tan SL, Potezny T, Li JY. The successful use of rituximab in crescentic IgA nephropathy with concurrent ANCA positivity. Nephrology (Carlton). 2022;27:216–7.

Article  CAS  PubMed  Google Scholar 

Kim JY, Choi H, Kim MK, Lee SB, Park YB, Lee SW. Clinical significance of ANCA positivity in patients with IgA vasculitis: a retrospective monocentric study. Rheumatol Int. 2019;39:1927–36.

Article  CAS  PubMed  Google Scholar 

Takeuchi S, Kawakami T, Okano T, et al. Elevated myeloperoxidase-DNA complex levels in sera of patients with IgA vasculitis. Pathobiology. 2022;89:23–8.

Article  CAS  PubMed  Google Scholar 

Yu JH, Lee KB, Lee JE, et al. A case of elderly-onset Crescentic Henoch-Schönlein purpura nephritis with hypocomplementemia and positive MPO-ANCA. J Korean Med Sci. 2012;27:957–60.

Article  PubMed  PubMed Central  Google Scholar 

Nagasaka T, Miyamoto J, Ishibashi M, Chen KR. MPO-ANCA- and IgA-positive systemic vasculitis: a possibly overlapping syndrome of microscopic polyangiitis and Henoch-Schoenlein purpura. J Cutan Pathol. 2009;36:871–7.

Article  PubMed  Google Scholar